Marginal Zone Lymphoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC,

DelveInsight's "Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of MZL, historical and forecasted epidemiology as well as MZL market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Marginal Zone Lymphoma Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Marginal Zone Lymphoma Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Marginal Zone Lymphoma Market Report
• In April 2025, Hutchison Medipharma Limited announced a Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL). Relapse / refractory is defined as such a situation when a patient has not achieved response (CR or PR) after the latest line of systemic treatment, or has disease progress (PD) or relapse after achieving response.
• In April 2025, Incyte Corporation conducted a phase 3 study to evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.
• In April 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
• Among the 7MM, the US accounted for the highest incidence cases of MZL in 2023, with more than ~8,000 cases; these cases are expected to increase during the forecast period.
• Among gender-specific incidence cases of MZL, males stand out as major contributors.
• MALT lymphoma has the highest incident population with ~70% cases followed by SMZL and NMZL, in 2023 in the US.
• Among the stage-specific incident cases of MZL, Stage III-IV has the highest incident population followed by Stage I and Stage II in 2023 in the US.
• The leading Marginal Zone Lymphoma Companies such as Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others.
• Promising Marginal Zone Lymphoma Therapies such as REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others.

Stay ahead in the competitive landscape of the Marginal Zone Lymphoma Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Marginal Zone Lymphoma Treatment Market Size- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marginal Zone Lymphoma Epidemiology Segmentation in the 7MM
• Total Prevalence of Marginal Zone Lymphoma
• Prevalent Cases of Marginal Zone Lymphoma by severity
• Gender-specific Prevalence of Marginal Zone Lymphoma
• Diagnosed Cases of Episodic and Chronic Marginal Zone Lymphoma

Download the report to understand which factors are driving Marginal Zone Lymphoma epidemiology trends @ Marginal Zone Lymphoma Prevalence- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marginal Zone Lymphoma Marketed Drugs
• REVLIMID (lenalidomide): Bristol-Myers Squibb
REVLIMID is an immune-modulating therapy with proven anti-myeloma effects. The drug is an oral therapy that was shown to work in 3 ways in animal models and in vitro, it helps the immune system recognize and destroy myeloma cells. Targets and kills myeloma cells and helps prevent new myeloma cell growth by starving them of blood. In May 2019, the FDA approved REVLIMID in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated MZL. Moreover, in December 2019, the European Commission Approval for REVLIMID in combination with rituximab for the treatment of adult patients with previously treated MZL.

• UKONIQ (umbralisib): TG Therapeutics
UKONIQ is the first and only oral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon. PI3K-delta is known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking, and immunity and is expressed in both normal and malignant B-cells. CK1-epsilon is a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies. In February 2021, the US FDA granted accelerated approval to umbralisib, a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.

Marginal Zone Lymphoma Emerging Drugs
• Tafasitamab: Incyte Corporation
Tafasitamab is a humanized Fc-modified CD19-targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb-engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Currently, the drug is being investigated in Phase III for marginal zone lymphoma.

• YESCARTA (axicabtagene ciloleucel): Gilead Sciences
YESCARTA, a CD19-directed genetically modified autologous T-cell immunotherapy, binds to CD19-expressing cancer cells and normal B-cells. In September 2020, Gilead Sciences subsidiary, Kite submitted a supplemental Biologics License Application (sBLA) to the FDA for YESCARTA for the treatment of r/r FL and MZL after two or more prior lines of systemic therapy. ZUMA-5 is a Phase II, multi-center, single-arm study of YESCARTA in patients with iNHL including follicular lymphoma (FL) and marginal zone lymphoma (MZL).

• BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
BREYANZI is an investigational CAR-T-cell therapy designed to target CD19, a surface glycoprotein expressed during normal B-cell development. Liso-cel CAR-T-cells aim to target and kill non-Hodgkin lymphoma cells through a CAR construct that includes an anti-CD19 single-chain variable fragment (scFv) targeting domain for antigen specificity, a transmembrane domain, a 4-1BB costimulatory domain hypothesized to increase T-cell proliferation and persistence, and a CD3-zeta T-cell activation domain. Currently, the drug is investigated in Phase II for the treatment of relapsed/refractory marginal zone lymphoma.

To learn more about Marginal Zone Lymphoma treatment guidelines, visit @ Marginal Zone Lymphoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marginal Zone Lymphoma Drugs Market Insights
In the realm of drug classes for MZL, several categories stand out. Monoclonal antibodies (mAbs) like rituximab target specific proteins in cancer cells, aiding in their destruction. Immunomodulatory agents such as lenalidomide enhance immune responses against cancer cells. Emerging therapies like chimeric antigen receptor (CAR) T-cell therapies show promise by harnessing engineered immune cells to target cancer cells. Traditional chemotherapy agents remain a part of treatment regimens, particularly in aggressive disease or when other therapies fail. Understanding these drug classes is essential for tailoring effective treatment strategies for MZL patients.

Marginal Zone Lymphoma Market Outlook
Marginal Zone Lymphoma treatment selection for a patient with Marginal Zone Lymphoma depends on the type, stage, and location of the disease. Due to the slow nature of progression, most patients tend to present before developing significant complications. In the rare cases of life or organ-threatening MZL, high-dose corticosteroids (for example, dexamethasone 40 mg daily) can be used to temporize matters before starting more definitive (Immuno) chemotherapy or radiotherapy. Treatment of indolent lymphoma should be individualized according to the disease subtype, presentation, comorbid conditions, and patient preferences. When possible, the goal of therapy is to cure the disease and/or prolong survival. In all cases, the goal should be to improve quality of life; care must be taken to avoid overtreatment.

Explore the dynamics of the Marginal Zone Lymphoma Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Marginal Zone Lymphoma Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Marginal Zone Lymphoma Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Marginal Zone Lymphoma Companies- Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
• Marginal Zone Lymphoma Therapies- REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others.
• Marginal Zone Lymphoma Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Marginal Zone Lymphoma Unmet Needs, KOL's views, Analyst's views, Marginal Zone Lymphoma Market Access and Reimbursement

To know more about Marginal Zone Lymphoma Companies working in the treatment market, visit @ Marginal Zone Lymphoma Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Marginal Zone Lymphoma Market Report Introduction
3 Marginal Zone Lymphoma Executive Summary
4 Key Events
5 Marginal Zone Lymphoma Epidemiology and Market Forecast Methodology
6 Marginal Zone Lymphoma Market Overview at a Glance
7 Marginal Zone Lymphoma Market Disease Background and Overview
8 Marginal Zone Lymphoma Epidemiology and Patient Population
9 Marginal Zone Lymphoma Patient Journey
10 Marginal Zone Lymphoma Marketed Products
11 Marginal Zone Lymphoma Emerging Drugs
12 Marginal Zone Lymphoma: Seven Major Market Analysis
13 Marginal Zone Lymphoma Unmet Needs
14 Marginal Zone Lymphoma SWOT Analysis
15 Marginal Zone Lymphoma KOL Views
16 Marginal Zone Lymphoma Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/implantable-cardiac-monitors-market
Sleep Tech Devices Market- https://www.delveinsight.com/report-store/sleep-tech-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.